



reference

L16 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1999:139868 HCAPLUS  
DOCUMENT NUMBER: 130:196958  
TITLE: Preparation of 3-tert-butyl-L-tyrosinamide-containing  
peptides and related compounds exhibiting a motilin  
receptor antagonism  
INVENTOR(S): Kotake, Ken-ichiro; Kozono, Toshiro; Sato,  
Tsutomu; Takanashi, Hisanori  
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan  
SOURCE: PCT Int. Appl., 144 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND              | DATE     | APPLICATION NO.  | DATE       |
|---|-------------------|----------|------------------|------------|
| -----   | ----              | -----    | -----            | -----      |
| WO 9909053  | A1                | 19990225 | WO 1998-JP3627   | 19980814   |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,<br>DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, KE, KG, KR,<br>KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,<br>PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,<br>US, UZ, VN, YU, ZW |                   |          |                  |            |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,<br>FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,<br>CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  |                   |          |                  |            |
| TW 460478   | B                 | 20011021 | TW 1998-87113211 | 19980811   |
| CA 2301687  | A1                | 19990225 | CA 1998-2301687  | 19980814   |
| AU 9886490  | A                 | 19990308 | AU 1998-86490    | 19980814   |
| AU 741216   | B2                | 20011129 |                  |            |
| JP 2000044595   | A                 | 20000215 | JP 1998-229586   | 19980814   |
| JP 3583928  | B2                | 20041104 |                  |            |
| EP 1006122  | A1                | 20000607 | EP 1998-937826   | 19980814   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, FI  |                   |          |                  |            |
| US 6255285  | B1                | 20010703 | US 2000-485620   | 20000215   |
| PRIORITY APPLN. INFO.:  |                   |          | JP 1997-255879   | A 19970815 |
|   |                   |          | JP 1998-186802   | A 19980528 |
|   |                   |          | WO 1998-JP3627   | W 19980814 |
| OTHER SOURCE(S):  | MARPAT 130:196958 |          |                  |            |
| GI  |                   |          |                  |            |

Updated Search

reference



AB Phenethylamine derivs. represented by general formula [I; wherein A represents an amino acid or  $\alpha$ -substituted amino acid residue; R1 represents R6CO, (un)substituted C2-7 linear or branched alkyl, C3-8 alkenyl, or C3-8 alkynyl; R2 represents hydrogen, C1-3 linear or branched alkyl; R3 represents COR7, (un)substituted C1-5 linear or branched alkyl, C2-5 alkenyl, or C2-5 alkynyl; R4 represents H, C1-6 linear or branched alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R5 represents hydroxy or C1-4 n-alkoxy; R6 represents (un)substituted C1-6 linear or branched alkyl, C2-7 alkenyl, or C2-7 alkynyl, optionally benzene- or heterocyclic ring-condensed C3-7 cycloalkyl, (un)substituted C6-12 aromatic ring, (un)substituted C3-12 (un)saturated heterocyclic ring, (un)substituted NH2, (un)substituted linear or branched C1-5 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, etc.; and R7 represents H, (un)substituted C1-5 linear or branched alkyl, C3-7 cycloalkyl, (un)substituted NH2, OH, linear or branched alkyl C1-6 alkoxy, or C3-7 cycloalkyloxy] are prepared Also claimed are a motilin receptor antagonist, an inhibitor of digestive tract motility, and a remedy for high blood motilin. They are also useful for the treatment of irritable bowel syndrome. Thus,  $\alpha$ -methyl-N-[2-(3-tert-butyl-4-hydroxyphenyl)-1-methylethyl]-L-valinamide was condensed with Boc-Phe-OH using HOBt and DIC in DMF at room temperature for 2.5 days followed by deprotection with CF3CO2H in CH2Cl2 to give the title compound (II). II in vitro showed IC50 of 1.9 nM for inhibiting the binding of [125I]motilin motilin receptor preparation from rabbit ileum mucous membrane.

IT 220806-45-1P 220806-47-3P 220806-49-5P  
 220806-51-9P 220806-59-7P 220806-61-1P  
 220806-63-3P 220806-71-3P 220806-75-7P  
 220806-77-9P 220806-79-1P 220806-81-5P  
 220806-83-7P 220806-85-9P 220806-87-1P  
 220806-89-3P 220806-91-7P 220806-93-9P

Updated Search

reference

220806-95-1P 220806-97-3P 220806-99-5P  
220807-01-2P 220807-03-4P 220807-05-6P  
220807-07-8P 220807-09-0P 220807-11-4P  
220807-19-2P 220808-16-2P 220808-17-3P  
220808-18-4P 220808-19-5P 220808-20-8P  
220808-27-5P 220808-28-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 3-tert-butyl-L-tyrosinamide-containing peptide compds. as motilin receptor antagonists, inhibitors of digestive tract motility, and remedy for high blood motilin)

RN 220806-45-1 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-L-phenylalanyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-44-0

CMF C31 H38 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-47-3 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-L-valyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

Updated Search

reference


CRN 220806-46-2  
CMF C27 H38 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-49-5 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-alanyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 220806-48-4  
CMF C25 H34 N4 O4

Absolute stereochemistry.

Updated Search


reference



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-51-9 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-L-leucyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-50-8

CMF C28 H40 N4 O4

Absolute stereochemistry.




CM 2

Updated Search

reference

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-59-7 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-tyrosyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-58-6  
CMF C31 H38 N4 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-61-1 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-(αS)-α-aminobenzenebutanoyl-3-  
(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

Updated Search


reference

CM 1

CRN 220806-60-0

CMF C32 H40 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-63-3 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-3-(2-thienyl)-L-alanyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-62-2

CMF C29 H36 N4 O4 S

Absolute stereochemistry.

Updated Search


reference



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-71-3 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-L-isoleucyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-70-2

CMF C28 H40 N4 O4

Absolute stereochemistry.




CM 2

Updated Search



reference

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-75-7 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-3-cyclohexyl-L-alanyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-74-6  
CMF C31 H44 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-77-9 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-3-methyl-L-valyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

Updated Search


reference

CM 1

CRN 220806-76-8

CMF C28 H40 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-79-1 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-L- $\alpha$ -aspartyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-78-0

CMF C26 H34 N4 O6

Absolute stereochemistry.

Updated Search


reference



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-81-5 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-L-α-glutamyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-80-4

CMF C27 H36 N4 O6

Absolute stereochemistry.




CM 2

Updated Search

reference

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-83-7 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-5-carboxy-L-norvalyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-82-6  
CMF C28 H38 N4 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-85-9 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-asparaginyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

Updated Search

reference


CRN 220806-84-8  
CMF C26 H35 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-87-1 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-glutaminyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-86-0  
CMF C27 H37 N5 O5

Absolute stereochemistry.




Updated Search

reference

CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-89-3 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-6-oxo-L-lysyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-88-2  
CMF C28 H39 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-91-7 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-(2S)-2,4-diaminobutanoyl-3-(1,1-  
dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


Updated Search

reference

CM 1


CRN 220806-90-6  
CMF C26 H37 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-93-9 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-ornithyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 220806-92-8  
CMF C27 H39 N5 O4

Absolute stereochemistry.

Updated Search


reference



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-95-1 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-L-lysyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-94-0

CMF C28 H41 N5 O4

Absolute stereochemistry.




CM 2

Updated Search



reference

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-97-3 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-seryl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-96-2  
CMF C25 H34 N4 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-99-5 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-homoseryl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

Updated Search

reference


CRN 220806-98-4  
CMF C26 H36 N4 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 220807-01-2 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-threonyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220807-00-1  
CMF C26 H36 N4 O5

Absolute stereochemistry.




Updated Search

reference

CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 220807-03-4 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-(2S)-2-aminobutanoyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220807-02-3  
CMF C26 H36 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220807-05-6 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-norvalyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

Updated Search


reference

CM 1

CRN 220807-04-5

CMF C27 H38 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220807-07-8 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-L-methionyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220807-06-7

CMF C27 H38 N4 O4 S

Absolute stereochemistry.

Updated Search


reference



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220807-09-0 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-L-histidyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220807-08-9

CMF C28 H36 N6 O4

Absolute stereochemistry.




CM 2

Updated Search

reference

CRN 76-05-1  
CMF C2 H F3 O2




RN 220807-11-4 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-tryptophyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220807-10-3  
CMF C33 H39 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 220807-19-2 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-  
(9CI) (CA INDEX NAME)

Updated Search

reference


Absolute stereochemistry.



RN 220808-16-2 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-L-valyl-3-(1,1-dimethylethyl)-Nα-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-17-3 HCAPLUS

CN L-Valinamide, L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-18-4 HCAPLUS

Updated Search

reference

CN L-Tyrosinamide, L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-  
N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-19-5 HCAPLUS

CN L-Valinamide, N-methyl-L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-  
hydroxyphenyl]-1-methylethyl]-N2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-20-8 HCAPLUS

CN L-Valinamide, L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-  
hydroxyphenyl]-1-methylethyl]-N,N2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search



reference


RN 220808-27-5 HCAPLUS  
CN L-Tyrosinamide, N-[(2S)-2-amino-3-phenylpropyl]-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220808-28-6 HCAPLUS  
CN Butanamide, N-[(1S)-2-amino-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-2-[[ (2S)-2-amino-3-phenylpropyl]amino]-3-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 220808-36-6P 220808-44-6P 220808-74-2P  
220808-80-0P 220808-85-5P 220808-89-9P  
220808-90-2P 220808-96-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of 3-tert-butyl-L-tyrosinamide-containing peptide compds. as  
motilin receptor antagonists, inhibitors of digestive tract motility,  
and remedy for high blood motilin)  
RN 220808-36-6 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-  
valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


reference



RN 220808-44-6 HCAPLUS

CN L-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-74-2 HCAPLUS

CN L-Tyrosinamide, N-[(2S)-3-phenyl-2-[[ (phenylmethoxy)carbonyl]amino]propyl]-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-80-0 HCAPLUS

Updated Search

reference


CN 2,5,8,11-Tetraazadodecanedioic acid,  
9-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-6-(1-methylethyl)-7-oxo-  
3-(phenylmethyl)-, 1,12-bis(phenylmethyl) ester, (3S,6S,9S)- (CA INDEX  
NAME)

Absolute stereochemistry.



RN 220808-85-5 HCAPLUS  
CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N2-methyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 220808-89-9 HCAPLUS  
CN L-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-  
valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


reference



RN 220808-90-2 HCAPLUS

CN L-Valinamide, N-(1,1-dimethylethyl)-L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-96-8 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N,N2-dimethyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



Updated Search

reference

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Updated Search